Drug Profile
Caspofungin - Merck & Co
Alternative Names: Cancidas; Cansidas; Caspofungin acetate; Caspofungin MSD; L 743792; L 743872; MK 0991; MK 991Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antifungals; Echinocandins
- Mechanism of Action Glucan synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Candidaemia; Candidiasis; Invasive bronchopulmonary aspergillosis; Mycoses
Most Recent Events
- 17 Feb 2021 No development reported - Phase-II for Candidiasis (In infants, In neonates) in Bulgaria, USA, Colombia, Turkey (IV)
- 03 Oct 2018 Efficacy and safety data from a phase II trial in Candidiasis presented at the IDWeek 2018 (IDW-2018)
- 07 Mar 2018 Merck terminates a phase II trial in Invasive candidiasis in USA, Columbia, Bulgaria and Turkey due to operational feasibility following low recruitment due to changing epidemiology of disease (NCT01945281)